The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer

Clin Endocrinol (Oxf). 2005 Sep;63(3):263-6. doi: 10.1111/j.1365-2265.2005.02332.x.

Abstract

Objective: Familial nonmedullary thyroid cancer (FNMTC) is relatively common but its predisposing genetic alteration is unclear. As the somatic T1799A BRAF mutation is highly prevalent in papillary thyroid cancer, the aim was to test whether this mutation was a susceptibility mutation for FNMTC.

Subjects and methods: The T1799A BRAF mutation as a possible germline mutation was examined in 40 subjects from 23 families with a history of FNMTC. Direct DNA sequencing was performed on white blood cell DNA samples to analyse the mutation status.

Results: No T1799A BRAF mutation was found in this group of subjects as germline mutation.

Conclusion: The T1799A BRAF mutation is not a germline mutation or susceptibility genetic event for FNMTC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Carcinoma, Papillary / genetics*
  • Child
  • DNA Mutational Analysis
  • Female
  • Genetic Predisposition to Disease
  • Germ-Line Mutation*
  • Humans
  • Male
  • Middle Aged
  • Mutation*
  • Pedigree
  • Proto-Oncogene Proteins B-raf / genetics*
  • Thyroid Neoplasms / genetics*

Substances

  • Proto-Oncogene Proteins B-raf